Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer

Auger radiopharmaceutical therapy is a promising strategy for micrometastatic disease given high linear energy transfer and short range in tissues, potentially limiting normal tissue toxicities. We previously demonstrated anti-tumor efficacy of a small-molecule Auger electron emitter targeting the prostate-specific membrane antigen (PSMA), 2-[3-[1-carboxy-5-(4-[125I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid), or 125I-DCIBzL, in a mouse xenograft model. Here, we investigated the therapeutic efficacy, long-term toxicity, and biodistribution of 125I-DCIBzL in a micrometastatic model of prostate cancer (PC). Methods: To test the therapeutic efficacy of 125I-DCIBzL in micrometastatic PC, we used a murine model of human metastatic PC in which PSMA+ PC3-ML cells expressing firefly luciferase were injected intravenously in NSG mice to form micrometastatic deposits. One week later, 0, 0.37, 1.85, 3.7, 18.5, 37, or 111 MBq of 125I-DCIBzL was administered (intravenously). Metastatic tumor burden was assessed using bioluminescence imaging (BLI). Long-term toxicity was evaluated via serial weights and urinalysis of non-tumor-bearing mice over a 12-month period, as well as final necropsy. Results: In the micrometastatic PC model, activities of 18.5 MBq 125I-DCIBzL and above significantly delayed development of detectable metastatic disease by BLI and prolonged survival in mice. Gross metastases were detectable in control mice and those treated with 0.37-3.7 MBq 125I-DCIBzL at a median of 2 weeks post-treatment, versus 4 weeks for those treated with 18.5-111 MBq 125I-DCIBzL (P<0.0001 by log-rank test). Similarly, treatment with ≥18.5 MBq 125I-DCIBzL yielded a median survival of 11 weeks, compared with 6 weeks for control mice (P<0.0001). At 12 months, there was no appreciable toxicity via weight, urinalysis, or necropsy evaluation in mice treated with any activity of 125I-DCIBzL, which represents markedly less toxicity than the analogous PSMA-targeted α-particle emitter. Macro-to-microscale dosimetry modeling demonstrated lower absorbed dose in renal cell nuclei versus tumor cell nuclei due to lower levels of drug uptake and cellular internalization in combination with the short range of Auger emissions. Conclusion: PSMA-targeted radiopharmaceutical therapy with the Auger emitter 125I-DCIBzL significantly delayed development of detectable metastatic disease and improved survival in a micrometastatic model of PC, with no long-term toxicities noted at 12 months, suggesting a favorable therapeutic ratio for treatment of micrometastatic PC.

[1]  F. Bénard,et al.  Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model , 2018, The Journal of Nuclear Medicine.

[2]  D. O’Keefe,et al.  A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies , 2018, The Journal of Nuclear Medicine.

[3]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[4]  M. Brechbiel,et al.  (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy , 2016, The Journal of Nuclear Medicine.

[5]  K. Någren,et al.  Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery , 2016, Theranostics.

[6]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[7]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[8]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[9]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[10]  M. Pomper,et al.  Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen , 2015, The Journal of Nuclear Medicine.

[11]  C. Pinkert Transgenic Animal Technology: A Laboratory Handbook , 2014 .

[12]  N. Moins,et al.  Evaluation of two 125I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma , 2014, Investigational New Drugs.

[13]  G. Lockwood,et al.  Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. , 2014, American journal of nuclear medicine and molecular imaging.

[14]  Steve D. M. Brown,et al.  Analysis of Phenotype , 2014 .

[15]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[16]  S. Hotte,et al.  Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  Larson,et al.  Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer , 2013 .

[18]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[19]  H. Song,et al.  A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry , 2012, Physics in medicine and biology.

[20]  Steve Y. Cho,et al.  GCPII imaging and cancer. , 2012, Current medicinal chemistry.

[21]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[22]  A. Kassis Molecular and cellular radiobiological effects of Auger emitting radionuclides. , 2011, Radiation protection dosimetry.

[23]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[24]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[25]  John C Roeske,et al.  Small-scale dosimetry: challenges and future directions. , 2008, Seminars in nuclear medicine.

[26]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[27]  Manuel Bardiès,et al.  Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons , 2008, Radiation research.

[28]  N. Rao,et al.  Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability , 2008, Molecular Cancer Therapeutics.

[29]  K Eckerman,et al.  ICRP Publication 107. Nuclear decay data for dosimetric calculations. , 2008, Annals of the ICRP.

[30]  Ming Zhou,et al.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. , 2006, Urology.

[31]  A. Kassis The Amazing World of Auger Electrons , 2004, International journal of radiation biology.

[32]  S. Adelstein,et al.  Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. , 2003, Cancer biotherapy & radiopharmaceuticals.

[33]  George Sgouros,et al.  MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.

[35]  E. Woltering,et al.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. , 2002, Seminars in nuclear medicine.

[36]  K. Oberg,et al.  Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  T. Wheldon,et al.  Targeted radiotherapy using Auger electron emitters. , 1996, Physics in medicine and biology.

[39]  M. Stearns,et al.  Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. , 1991, Differentiation; research in biological diversity.